Aono T, Miyake A, Yasuda T S, Koike K, Kurachi K
Acta Endocrinol (Copenh). 1979 Aug;91(4):591-600. doi: 10.1530/acta.0.0910591.
Five mg of bromocriptine was administered for 3 weeks to 8 hyperprolactinaemic women with galactorrhoea-amernorrhoea, in whom the response of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to 100 micrograms of iv LH-releasing hormone (LH-RH) had been evaluated. Twenty mg of conjugated oestrogen (Premarin) was injected iv any day between the 10th and 12th day from the initiation of the treatment, and serum LH levels were serially determined for 120 h. Hyperresponse of LH with normal FSH response to LH-RH was observed in most patients. Bromocriptine treatment for 10 to 12 days significantly suppressed mean (+/- SE) serum prolactin (PRL) levels from 65.1 +/- 23.0 to 10.4 +/- 2.0 ng/ml, while LH (12.6 +/- 2.1 to 24.8 +/- 5.9 mIU/ml) and oestradiol (40.1 +/- 7.6 to 111.4 +/- 20.8 pg/ml) levels increased significantly. Patients on bromocriptine treatment showed LH release with a peak at 48 h after injection of Premarin. The mean per cent increases in LH were significantly higher than those in untreated patients with galactorrhoea-amenorrhoea between 32 and 96 h after the injection. The present results seem to suggest that the restoration of LH-releasing response to oestrogen following suppression of PRL by bromocriptine may play an important role in induction of ovulation in hyperprolactinaemic patients with galactorrhoea-amenorrhoea.
对8名患有溢乳-闭经的高泌乳素血症女性给予5毫克溴隐亭治疗3周，此前已评估了她们血清促黄体生成素（LH）和促卵泡生成素（FSH）对100微克静脉注射促黄体生成素释放激素（LH-RH）的反应。在治疗开始后的第10至12天之间的任何一天静脉注射20毫克结合雌激素（普雷马林），并连续120小时测定血清LH水平。大多数患者观察到LH对LH-RH的高反应以及FSH的正常反应。溴隐亭治疗10至12天可使平均（±标准误）血清催乳素（PRL）水平从65.1±23.0显著降至10.4±2.0纳克/毫升，而LH（12.6±2.1至24.8±5.9毫国际单位/毫升）和雌二醇（40.1±7.6至111.4±20.8皮克/毫升）水平显著升高。接受溴隐亭治疗的患者在注射普雷马林后48小时出现LH释放高峰。注射后32至96小时内，LH的平均升高百分比显著高于未治疗的溢乳-闭经患者。目前的结果似乎表明，溴隐亭抑制PRL后雌激素诱导LH释放反应的恢复可能在患有溢乳-闭经的高泌乳素血症患者的排卵诱导中起重要作用。
